lutetium and Neoplasms
lutetium has been researched along with Neoplasms in 52 studies
Research
Studies (52)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.92) | 18.7374 |
| 1990's | 2 (3.85) | 18.2507 |
| 2000's | 16 (30.77) | 29.6817 |
| 2010's | 24 (46.15) | 24.3611 |
| 2020's | 9 (17.31) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Garnuszek, P; Karczmarczyk, U; Maurin, M; Sawicka, A; Wojdowska, W | 1 |
| Abedi, SM; Hosseinimehr, SJ; Khorramimoghaddam, A; Molavipordanjani, S; Mousavi, T; Talebpour Amiri, F | 1 |
| Alcocer-Ávila, M; Champion, C; Hindié, E; Larouze, A; Morgat, C | 1 |
| Al-Baddai, S; Chen, S; Götz, TI; Kuwert, T; Lang, EW; Schmidkonz, C | 1 |
| Behe, M; Grob, NM; Mindt, TL; Schibli, R; Schmid, S | 1 |
| Belli, ML; Canali, E; Caroli, P; Celli, M; Cremonesi, M; Di Iorio, V; Ferrari, M; Grassi, I; Matteucci, F; Mezzenga, E; Nicolini, S; Paganelli, G; Sansovini, M; Sarnelli, A; Severi, S; Tardelli, E | 1 |
| Bernhardt, P; Cohrs, S; Fang, HY; Guzik, P; Müller, C; Schibli, R; Siwowska, K | 1 |
| Bassi, G; Biancofiore, I; Cazzamalli, S; Dakhel Plaza, S; Donckele, EJ; Elsayed, A; Gloger, A; Millul, J; Mock, J; Nadal, L; Neri, D; Pellegrino, C; Samain, F; Schmidt, E; Zana, A | 1 |
| Ai, X; Fu, L; Hao, P; Li, L; Wei, P; Zhang, J; Zhou, J | 1 |
| Cai, W; Cheng, L; Engle, JW; Ferreira, CA; He, Q; Kutyreff, CJ; Lan, X; Ni, D; Rosenkrans, ZT; Wei, H; Yu, B; Yu, F | 1 |
| Adumeau, P; Davydova, M; Zeglis, BM | 1 |
| Buxbaum, S; Fink, K; Maffey-Steffan, J; Mair, C; Nilica, B; Scarpa, L; Virgolini, IJ; Warwitz, B | 1 |
| Bednarz, B; Lee, D; Li, M; Schultz, MK | 1 |
| Alshehri, S; Fan, W; Garrison, JC; Neeley, TR; Zhang, W | 1 |
| Anderson, CJ; Berkman, CE; Choy, CJ; Geruntho, JJ; Kurland, BF; Langton-Webster, B; Latoche, JD; Laymon, CM; Ling, X; Rigatti, LH; Salamacha, N; Shen, D; Windish, HP; Wu, Y | 1 |
| Chen, X; Chen, Z; Huang, M; Huang, P; Li, R; Ma, E; Tu, D; Zheng, W; Zhou, S; Zhu, H | 1 |
| Díaz-Nieto, L; Ferro-Flores, G; Gómez-Oliván, L; Jiménez-Mancilla, N; Luna-Gutiérrez, M; Morales-Avila, E; Ocampo-García, B; Pedraza-López, M; Santos-Cuevas, C; Vilchis-Juárez, A | 1 |
| Celler, A; Grimes, J | 1 |
| Azorín-Vega, EP; Ferro-Flores, G; Ocampo-García, BE; Rojas-Calderón, EL; Zambrano-Ramírez, OD | 1 |
| Yoshikawa, K | 1 |
| Bandari, RP; Jiang, Z; Reynolds, TS; Smith, CJ | 1 |
| Knapp, FF; Pillai, AM | 1 |
| Banerjee, S; Knapp, FF; Pillai, MR | 1 |
| Amato, E; Baldari, S; Italiano, A; Leotta, S | 1 |
| Feron, O; Gallez, B; Lucas, S; Masereel, B; Michiels, C; Vander Borght, T | 1 |
| Huang, L; Satterlee, AB; Yuan, H | 1 |
| Cho, EH; Jung, SH; Lee, SY; Lim, JC | 1 |
| Dayton, PA; Huang, L; Rojas, JD; Satterlee, AB | 1 |
| Tweedle, MF | 1 |
| Bombardieri, E; Canevari, S; Coliva, A; Figini, M; Giussani, A; Luison, E; Seregni, E; Zacchetti, A | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Sarma, HD; Venakatesh, M | 1 |
| Grüll, H; Nicolay, K; Robillard, MS; van Duijnhoven, SM | 1 |
| de Jong, M; Konijnenberg, MW | 1 |
| Beran, M; Chinol, M; Eigner, S; Henke, KE; Laznicek, M; Laznickova, A; Melichar, F; Vera, DR | 1 |
| Cescato, R; Fani, M; Reubi, JC; Waser, B | 1 |
| Fani, M; Maecke, HR; Reubi, JC; Rivier, J; Schulz, S; Wang, X | 1 |
| MAEDA, T | 1 |
| Boerman, OC; Corstens, FH; Frielink, C; Goldenberg, DM; Oyen, WJ; Postema, EJ; Raemaekers, JM | 1 |
| Bossuyt, A; Caveliers, V; Everaert, H; Franken, PR; Lahoutte, T; Muylle, K; Vanhove, C | 1 |
| Boellaard, R; Comans, EF; Hoekstra, OS; Joshi, U; Miller, SD; Pijpers, RJ; Raijmakers, PG; Teule, GJ; van Lingen, A | 1 |
| Czernin, J; Dahlbom, M; Halpern, BS; Quon, A; Ratib, O; Schiepers, C; Silverman, DH; Waldherr, C | 1 |
| Boerdijk, SM; Paans, AM; Pruim, J; Willemsen, AT | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Kagiya, VT; Mukherjee, A; Nair, CK; Samuel, G; Sarma, HD; Venkatesh, M | 1 |
| Anderson, T; Atcher, R; Nayak, T; Norenberg, J | 1 |
| Auerbach, MA; Czernin, J; Dahlbom, M; Fueger, BJ; Halpern, BS; Ratib, O; Schiepers, C; Silverman, DH; Weber, WA | 1 |
| Ametamey, S; Bläuenstein, P; Grünberg, J; Honer, M; Knogler, K; Maecke, HR; Novak-Hofer, I; Schubiger, PA; Zimmermann, K | 1 |
| Badawi, RD; Dibos, PE; Gilbert, R; Line, BR; Lodge, MA | 1 |
| Nunn, AD; Panigone, S | 1 |
| Carrasquillo, JA; Chung, Y; Curt, G; Feuerstein, I; Milenic, DE; Mulligan, T; Paik, C; Perentesis, P; Reynolds, J; Schlom, J | 1 |
| Bakker, WH; Bugaj, JL; de Jong, M; Erion, JL; Konijnenberg, MW; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Schmidt, MA; Srinivasan, A | 1 |
Reviews
5 review(s) available for lutetium and Neoplasms
| Article | Year |
|---|---|
Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with
Topics: Antibodies, Monoclonal; Chelating Agents; Humans; Lutetium; Neoplasms; Radioimmunotherapy; Radioisotopes; Rituximab; Tissue Distribution | 2022 |
Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy.
Topics: Animals; Bombesin; Humans; Lutetium; Molecular Imaging; Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Bombesin | 2016 |
Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications.
Topics: Animals; Humans; Lutetium; Molecular Conformation; Neoplasms; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals | 2015 |
Preclinical animal research on therapy dosimetry with dual isotopes.
Topics: Animals; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Indium Radioisotopes; Lutetium; Neoplasms; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Yttrium Radioisotopes | 2011 |
Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Gastrin-Releasing Peptide; Humans; Lutetium; Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Bombesin | 2006 |
Trials
4 trial(s) available for lutetium and Neoplasms
| Article | Year |
|---|---|
Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology.
Topics: Adult; Aged; Aged, 80 and over; Equipment Design; Equipment Failure Analysis; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gamma Cameras; Humans; Lutetium; Male; Middle Aged; Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Silicates; Sodium Iodide; Transducers; Whole-Body Counting | 2004 |
Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.
Topics: Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lutetium; Male; Middle Aged; Neoplasms; Obesity; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Silicates; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage | 1995 |
Photodynamic therapy trial expands.
Topics: Acquired Immunodeficiency Syndrome; Female; Humans; Injections, Intravenous; Lighting; Lutetium; Male; Metalloporphyrins; Neoplasms; Photochemotherapy; Photosensitizing Agents; Sarcoma, Kaposi | 1996 |
Other Studies
43 other study(ies) available for lutetium and Neoplasms
| Article | Year |
|---|---|
The preclinical study of
Topics: Animals; Cell Line, Tumor; Humans; Lutetium; Mice; Mice, Nude; Neoplasms; Radiopharmaceuticals; Tissue Distribution | 2023 |
Membrane and Nuclear Absorbed Doses from
Topics: Humans; Lutetium; Neoplasms; Radioisotopes; Radiopharmaceuticals | 2023 |
A deep learning approach to radiation dose estimation.
Topics: Algorithms; Deep Learning; Glutamate Carboxypeptidase II; Humans; Lutetium; Monte Carlo Method; Neoplasms; Neural Networks, Computer; Organs at Risk; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Reproducibility of Results; Tissue Distribution; Tomography, X-Ray Computed | 2020 |
Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Gastrins; Humans; Lutetium; Mice; Neoplasms; Peptidomimetics; Protein Binding; Radioisotopes; Radiopharmaceuticals; Receptor, Cholecystokinin B; Triazoles | 2020 |
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Topics: Adult; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Prostate-Specific Antigen; Radioisotopes; Radiometry; Receptors, Peptide; Single Photon Emission Computed Tomography Computed Tomography | 2020 |
Promising potential of [
Topics: Animals; Cell Line, Tumor; Folic Acid; Immunotherapy; Lutetium; Mice; Neoplasms; Radioisotopes; Radiopharmaceuticals | 2021 |
An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Endopeptidases; Fibroblasts; Gene Expression; Gene Expression Regulation, Neoplastic; Isotope Labeling; Ligands; Lutetium; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms; Quinolines; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays | 2021 |
DNA-assisted upconversion nanoplatform for imaging-guided synergistic therapy and laser-switchable drug detoxification.
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; DNA; Female; HEK293 Cells; HeLa Cells; Humans; Hyperthermia, Induced; Luminescent Agents; Lutetium; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Polymers; Pyrroles; Sodium Fluoride | 2017 |
Efficient Uptake of
Topics: Drug Delivery Systems; Humans; Lutetium; Mitochondria; Multimodal Imaging; Nanoparticles; Neoplasms; Optical Imaging; Photochemotherapy; Polyethylene Glycols; Porphyrins; Positron-Emission Tomography; Radioisotopes; Theranostic Nanomedicine | 2018 |
Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability.
Topics: Animals; Chelating Agents; Humans; Immunoconjugates; Lutetium; Mesylates; Mice; Mice, Nude; Neoplasms; Positron-Emission Tomography; Radioisotopes; Sulfhydryl Compounds; Zirconium | 2018 |
Radiation exposure after
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Neoplasms; Octreotide; Organometallic Compounds; Organs at Risk; Prostate-Specific Antigen; Radiometry; Radiotherapy Dosage; Salivary Glands; Single Photon Emission Computed Tomography Computed Tomography; Whole Body Imaging | 2018 |
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes | 2018 |
Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.
Topics: Animals; Cathepsins; Enzyme Inhibitors; Female; HT29 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Lutetium; Mice, SCID; Neoplasms; Peptides; Radioisotopes; Radiopharmaceuticals; Receptors, Neurotensin; Tissue Distribution | 2019 |
Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Topics: Animals; Antigens, Surface; Drug Screening Assays, Antitumor; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Radioisotopes; Radiometry; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Single Photon Emission Computed Tomography Computed Tomography; Tissue Distribution; Xenograft Model Antitumor Assays | 2020 |
Lanthanide-doped LiLuF(4) upconversion nanoprobes for the detection of disease biomarkers.
Topics: Biomarkers; Biosensing Techniques; Cell Line, Tumor; Cell Survival; Chorionic Gonadotropin; Humans; Infrared Rays; Lanthanoid Series Elements; Lithium; Lutetium; Metal Nanoparticles; Microscopy, Confocal; Neoplasms; Tomography, X-Ray Computed | 2014 |
Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Chemoradiotherapy; Gold; Lutetium; Male; Metal Nanoparticles; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoconjugates; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Radioisotopes; Rats; Xenograft Model Antitumor Assays | 2014 |
Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques.
Topics: Algorithms; Computer Simulation; Female; Humans; Iodine Radioisotopes; Kidney; Liver; Lutetium; Male; Models, Biological; Monte Carlo Method; Neoplasms; Niacinamide; Octreotide; Radiation Dosage; Radiopharmaceuticals; Software; Technetium; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2014 |
Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
Topics: Fibrosis; Gold; HeLa Cells; Humans; Lutetium; Metal Nanoparticles; Models, Biological; Monte Carlo Method; Neoplasms; Octreotide; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Theranostic Nanomedicine | 2015 |
[C-11 imaging using LSO PET-CT].
Topics: Carbon Radioisotopes; Humans; Lutetium; Neoplasms; Positron-Emission Tomography; Silicates; Tomography, X-Ray Computed | 2007 |
Editorial: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease.
Topics: Chronic Disease; Humans; Lutetium; Neoplasms; Nuclear Medicine; Radioisotopes | 2015 |
A Monte Carlo approach to small-scale dosimetry of solid tumour microvasculature for nuclear medicine therapies with (223)Ra-, (131)I-, (177)Lu- and (111)In-labelled radiopharmaceuticals.
Topics: Capillaries; Indium Radioisotopes; Iodine Radioisotopes; Isotope Labeling; Lutetium; Monte Carlo Method; Neoplasms; Nuclear Medicine; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radium | 2015 |
Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
Topics: Algorithms; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Iodine Radioisotopes; Lung; Lung Neoplasms; Lutetium; Models, Statistical; Monte Carlo Method; Nanomedicine; Neoplasms; Radiation Pneumonitis; Radioimmunotherapy; Radioisotopes; Radiotherapy Planning, Computer-Assisted; Rhenium; Yttrium Radioisotopes | 2015 |
A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.
Topics: Animals; Apoptosis; Calcium Phosphates; Cell Line, Tumor; DNA Damage; Female; Humans; Lutetium; Mice; Mice, Nude; Nanoparticles; Neoplasms; NIH 3T3 Cells; Radioisotopes; Theranostic Nanomedicine; Tomography, Emission-Computed, Single-Photon; Tumor Microenvironment | 2015 |
An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
Topics: Animals; Cell Line, Tumor; Cholecystokinin; Heterografts; Humans; Lutetium; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Radioisotopes; Radioligand Assay; Receptors, Cholecystokinin | 2016 |
Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combination; Lutetium; Mice; Nanoparticles; Neoplasms; Radioisotopes; Stilbenes; Treatment Outcome | 2017 |
Peptide-targeted diagnostics and radiotherapeutics.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Cell Line; ErbB Receptors; Gadolinium; Humans; Lutetium; Male; Molecular Sequence Data; Neoplasms; Oligopeptides; Peptides; Positron-Emission Tomography; Prostatic Neoplasms; Protein Binding; Radiopharmaceuticals; Rats; Receptors, G-Protein-Coupled; Tuftsin | 2009 |
(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Carrier Proteins; Cell Line, Tumor; Female; Folate Receptors, GPI-Anchored; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Isotope Labeling; Lutetium; Maximum Tolerated Dose; Mice; Neoplasms; Radioimmunotherapy; Radioisotopes; Receptors, Cell Surface; Time Factors; Tissue Distribution; Transplantation, Heterologous; Tumor Burden; Yttrium Radioisotopes | 2009 |
A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Topics: Animals; Chelating Agents; Cross-Linking Reagents; Female; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Neoplasms; Porphyrins; Radioisotopes; Radionuclide Imaging; Treatment Outcome | 2010 |
Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
Topics: Animals; Biotransformation; Cell Line, Tumor; Cell-Penetrating Peptides; Female; Humans; Iodine Radioisotopes; Isotope Labeling; Lutetium; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2011 |
Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Neoplasm Transplantation; Neoplasms; Radioimmunotherapy; Radioisotopes; Rats; Rats, Wistar; Time Factors | 2011 |
Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
Topics: Amino Acid Sequence; Autoradiography; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Neoplasms; Oligopeptides; Protein Binding; Radioisotopes; Receptors, Somatostatin | 2011 |
Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
Topics: Animals; Female; HEK293 Cells; Humans; Indium Radioisotopes; Lutetium; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Octreotide; Organometallic Compounds; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Tissue Distribution | 2012 |
[TREATMENT WITH RADIOISOTOPES].
Topics: Ascites; Chromium Isotopes; Gold Isotopes; Heart Failure; Humans; Hydrothorax; Hyperthyroidism; Iodine Isotopes; Iridium; Lutetium; Myocardial Infarction; Neoplasms; Phosphorus Isotopes; Radioisotopes; Radiotherapy; Tantalum; Thyroid Neoplasms; Yttrium Isotopes | 1963 |
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Duodenum; Female; Femur; Humans; Iodine Radioisotopes; Kidney; Lectins; Liver; Lung; Lutetium; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Muscles; Neoplasm Transplantation; Neoplasms; Radioimmunotherapy; Radioisotopes; Rhenium; Sialic Acid Binding Ig-like Lectin 2; Spleen; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2003 |
Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
Topics: Dose-Response Relationship, Drug; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Lutetium; Male; Middle Aged; Neoplasms; Quality Control; Radiation Protection; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Silicates; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
186Re and high-specific-activity 177Lu available in North America.
Topics: Animals; Humans; Lutetium; Neoplasms; North America; Radioisotopes; Radiopharmaceuticals; Rhenium | 2004 |
Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.
Topics: Body Weight; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Posture; Prospective Studies; Radiopharmaceuticals; Silicates; Time Factors; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Source of impaired image quality in 3D whole-body FDG PET scanning.
Topics: Artifacts; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Quality Control; Radiation Protection; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Silicates; Whole-Body Counting | 2004 |
Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Fibrosarcoma; Hypoxia; Lutetium; Mice; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Triazoles | 2004 |
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2005 |
In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.
Topics: Animals; Copper Radioisotopes; Humans; Immunoconjugates; Immunoglobulin Fragments; Lutetium; Mice; Mice, Nude; Neoplasms; Neural Cell Adhesion Molecule L1; Neuroblastoma; Positron-Emission Tomography; Radioisotopes; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner.
Topics: Equipment Design; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lutetium; Male; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Silicates; Whole Body Imaging | 2006 |
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Topics: Adolescent; Adult; Aged; Female; Humans; Indium Radioisotopes; Lutetium; Male; Middle Aged; Neoplasms; Octreotide; Organometallic Compounds; Radiation Dosage; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin | 2001 |